Condition

Mismatch Repair Deficiency

ClinicalTrials.gov condition label

Clinical trials6
Recruiting2
Common interventions20
Lead sponsors shown6

Clinical trials

6 shown
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab MonotherapyNCT06362369 · 2024-08-23
RECRUITING
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryNCT03452774 · 2018-01-01
RECRUITING
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer TypesNCT06034860 · 2023-11-01
TERMINATED
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667 · 2018-12-11
ACTIVE_NOT_RECRUITING
A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077 · 2018-09-24
COMPLETED
Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerNCT02983578 · 2017-03-02
ACTIVE_NOT_RECRUITING

Common interventions

NivolumabDRUG2AlintegimodDRUG1Clinical Trial MatchingOTHER1DanvatirsenDRUG1DurvalumabBIOLOGICAL1INCAGN02390DRUG1IpilimumabDRUG1MT-8421DRUG1N-803 + AtezolizumabDRUG1N-803 + Atezolizumab + PD-L1 t-haNKDRUG1N-803 + AvelumabDRUG1N-803 + Avelumab + PD-L1 t-haNKDRUG1N-803 + Docetaxel + NivolumabDRUG1N-803 + Docetaxel + PembrolizumabDRUG1N-803 + DurvalumabDRUG1N-803 + Durvalumab + PD-L1 t-haNKDRUG1N-803 + NivolumabDRUG1N-803 + Nivolumab + PD-L1 t-haNKDRUG1N-803 + PembrolizumabDRUG1N-803 + Pembrolizumab + PD-L1 t-haNKDRUG1

Trial status mix

ACTIVE_NOT_RECRUITING2
RECRUITING2
COMPLETED1
TERMINATED1

Phase mix

PHASE13
PHASE23

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.